BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/21/2020 6:56:33 AM | Browse: 764 | Download: 920
|
Received |
|
2019-12-30 18:51 |
|
Peer-Review Started |
|
2019-12-30 18:52 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-02-29 22:27 |
|
Revised |
|
2020-03-05 15:34 |
|
Second Decision |
|
2020-04-03 12:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-04-04 02:53 |
|
Articles in Press |
|
2020-04-04 02:53 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-04-20 01:48 |
|
Publish the Manuscript Online |
|
2020-04-21 06:56 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Infectious Diseases |
Manuscript Type |
Minireviews |
Article Title |
Update on quinolone-containing rescue therapies for Helicobacter pylori infection
|
Manuscript Source |
Invited Manuscript |
All Author List |
Hideki Mori and Hidekazu Suzuki |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Hideki Mori, MD, PhD, Doctor, Postdoctoral Fellow, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Herestraat 49 Box 701, Leuven 3000, Belgium. hideki.mori@kuleuven.be |
Key Words |
Helicobacter pylori; Levofloxacin; Sitafloxacin; Moxifloxacin; gyrA; Vonoprazan |
Core Tip |
The efficacies of 7-d levofloxacin or moxifloxacin, -containing regimens are becoming less effective in recent years due to the increasing antibiotic resistance, which necessitates 10-d or 14-d regimens or bismuth containing regimen are needed to achieve sufficient eradication rates. gyrA mutation is the most sensitive marker for predicting successful eradication in using quinolone-containing therapies. Thus, analysis of gyrA mutation before treatments is recommended. Seven-day sitafloxacin-amoxicillin-vonoprazan triple therapy is the best choice for third-line treatment at present. |
Publish Date |
2020-04-21 06:56 |
Citation |
Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744 |
URL |
https://www.wjgnet.com/1007-9327/full/v26/i15/1733.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v26.i15.1733 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345